2012 Survey Highlights

  • A total of 120 completed surveys were incorporated into the final Global BioPharma Survey Report. 
  • Of those who responded, 31% were from pharmaceutical companies, 22% were from biotech companies, 9% were from academic institutions, 6% were from government, and 32% were from other organizations.
  • The survey covered assets at all stages of development and the report offers a wealth of information on early stage programs. In all, 24% of the deals addressed assets in the discovery phase and another 16% covered programs that were on an IND track but had not yet been filed. 
  • Approximately 65% of the deals were considered “Global” in scope.
  • The survey covered assets at all stages of development and the report offers a wealth of information on early stage programs. In all, 24% of the deals addressed assets in the discovery phase and another 16% covered programs that were on an IND track but had not yet been filed. 
Seminar Information
Seminar Date:
November 30, -0001
GLOBAL BIOPHARMA ROYALTY RATES AND DEAL TERMS SURVEY
Individual topic purchase: Selected